X4 Pharmaceuticals, Inc.

NASDAQ:XFOR

Biotechnology

Healthcare
$2.96 +1.49%

+$0.06 today

Market cap
$302.26M
Beta
0.37
P/E (TTM)
-5.2
EPS (TTM)
-$0.79
52W Low $1.35High $4.83

Volume 1.12M

Average 0.40M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$85.62M

FY 2025 · Annual

Investing Cash Flow

$8.15M

FY 2025 · Annual

-87.8% YoY

Financing Cash Flow

$238.63M

FY 2025 · Annual

+1075.9% YoY

Cash Flow Statement

USD
Metric
FY 2021
Dec 2021
FY 2022
Dec 2022
FY 2023
Dec 2023
FY 2024
Dec 2024
FY 2025
Dec 2025
Net Income(88.7M)(93.87M)(101.17M)(37.45M)(79.2M)
Depreciation & Amortization1.89M513K419K796K1.28M
Deferred Income Tax00000
Stock-Based Compensation05.2M8.69M8.2M4.3M
Change in Working Capital(1.5M)5.74M344K2.68M(2.58M)
Accounts Receivables000(1.07M)497K
Inventory000(2.82M)(1.66M)
Accounts Payables1.17M3.43M1.23M(286K)(2.98M)
Other Working Capital(2.66M)2.31M(890K)6.85M1.57M
Other Non-Cash Items17.4M5.32M(4.8M)(105.13M)(9.42M)
Operating Cash Flow(70.91M)(77.1M)(96.51M)(130.9M)(85.62M)
Capital Expenditures(615K)(103K)(60K)(7.33M)(3M)
Acquisitions (Net)00000
Purchases of Investments00(16.82M)(57.13M)(63.39M)
Sales of Investments002M26.45M74.54M
Other Investing Activities00098M0
Investing Cash Flow(615K)(103K)(14.88M)66.99M8.15M
Debt Repayment0(795K)20.44M20M0
Common Stock Issued76.25M122.63M60M294K238.53M
Common Stock Repurchased(2M)0000
Dividends Paid00000
Other Financing Activities0(4.61M)8.08M098K
Financing Cash Flow74.25M117.23M88.52M20.29M238.63M
Effect of Forex Changes90K(105K)99K(156K)213K
Net Change in Cash2.82M39.92M(22.78M)(43.77M)161.38M
Free Cash Flow(71.52M)(77.21M)(96.57M)(138.23M)(88.62M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$79.2M
+ D&A$1.3M
+ Stock-Based Comp$4.3M
+ Deferred Tax$0
- Working Capital-$2.6M
- Other Non-Cash-$9.4M
= Operating Cash Flow-$85.6M
- Capex-$3.0M
= Free Cash Flow-$88.6M

Analysis

FY2025 free cash flow is -$88.6M. FCF conversion is 111.9% of net income. Operating cash flow was -$85.6M, with capex of -$3.0M. The largest bridge item is Other Non-Cash at -$9.4M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 13, 2026
10-QQuarterly reportNov 4, 2026
8-KCurrent reportOct 29, 2026
4Statement of changes in beneficial ownershipOct 19, 2026
8-KCurrent reportOct 8, 2026

Does XFOR generate free cash flow?

X4 Pharmaceuticals, Inc. (XFOR) generated -$88.62M of free cash flow in fiscal 2025.

How much operating cash flow does XFOR produce?

Operating cash flow was -$85.62M, before capital expenditures of $3.00M.